Salloum E, Cooper D L, Howe G, Lacy J, Tallini G, Crouch J, Schultz M, Murren J
Department of Medicine, Yale University School of Medicine, Yale Cancer Center, New Haven, CT 06520-8032.
J Clin Oncol. 1996 Jun;14(6):1943-9. doi: 10.1200/JCO.1996.14.6.1943.
To determine the clinicopathologic features of lymphoproliferative disorders (LPD) that occur in the setting of methotrexate (MTX) therapy for rheumatic diseases (RD) and to define the relationship between the presence of Epstein-Barr virus (EBV) in tumor cells and the response of LPD to MTX withdrawal.
In addition to nine new cases, we analyzed 28 cases previously reported in the literature of LPD in patients receiving MTX for RD. In addition to MTX, immunosuppressive therapy included corticosteroids in 19 patients, azathioprine in three, and cyclosporine in one. Extranodal disease was identified in 16 patients, but none had CNS involvement. Pathologic findings included five cases of Hodgkin's disease and seven low-grade lymphomas. The remaining patients had intermediate or aggressive lymphomas. In situ hybridization studies (ISHS) for EBV-RNA transcripts were positive in 12 of 27 patients (44%).
Among 37 patients, 16 were initially observed after MTX withdrawal without additional antitumor therapy. Six achieved a spontaneous complete remission (CR), three had a partial response (PR), one had a minimal response, and six had no response to MTX withdrawal. Of 10 responding patients, EBV was detected by ISHS (n = 6) or polymerase chain reaction (PCR) (n = 2); one patient had a CR despite the absence of EBV by PCR and one had a CR but did not have viral assays performed. Only one of six patients with negative EBV by ISHS or PCR responded to MTX withdrawal.
MTX withdrawal and observation for a short period should be considered in the initial management of patients who develop LPD while on MTX therapy. Responses were consistently observed, but not limited to patients in whom EBV was detected by ISHS or PCR. Further studies are required to confirm these findings and to evaluate the role for EBV in LPD that occur in patients receiving MTX.
确定在甲氨蝶呤(MTX)治疗风湿性疾病(RD)过程中发生的淋巴增殖性疾病(LPD)的临床病理特征,并明确肿瘤细胞中爱泼斯坦-巴尔病毒(EBV)的存在与LPD对停用MTX的反应之间的关系。
除9例新病例外,我们分析了文献中先前报道的28例接受MTX治疗RD的患者发生LPD的病例。除MTX外,免疫抑制治疗包括19例患者使用皮质类固醇,3例使用硫唑嘌呤,1例使用环孢素。16例患者出现结外病变,但均无中枢神经系统受累。病理结果包括5例霍奇金病和7例低度淋巴瘤。其余患者患有中度或侵袭性淋巴瘤。27例患者中有12例(44%)的EBV-RNA转录原位杂交研究(ISHS)呈阳性。
37例患者中,16例在停用MTX后未接受额外抗肿瘤治疗的情况下进行了初始观察。6例实现了自发完全缓解(CR),3例有部分缓解(PR),1例有最小反应,6例对停用MTX无反应。在10例有反应的患者中,通过ISHS(n = 6)或聚合酶链反应(PCR)(n = 2)检测到EBV;1例患者尽管PCR检测未发现EBV但实现了CR,1例患者实现了CR但未进行病毒检测。ISHS或PCR检测EBV阴性的6例患者中只有1例对停用MTX有反应。
对于在MTX治疗期间发生LPD的患者,初始管理时应考虑停用MTX并进行短期观察。一致观察到有反应,但不仅限于通过ISHS或PCR检测到EBV的患者。需要进一步研究来证实这些发现,并评估EBV在接受MTX治疗患者发生的LPD中的作用。